Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Genetic diagnosis of SBMA with symptomatic muscle weakness~* Able to complete 2 minute timed walk~* Serum IGF-1 level less than or equal to 170 ng/mL~Key Exclusion Criteria:~* Medically treated diabetes mellitus or known history of hypoglycemia~* History of Bell's palsy~* Treatment with systemic steroids \> 10 mg/day (or equivalent dose); androgens or androgen reducing agents; systemic beta agonists; or other muscle anabolic drugs within the previous 3 months~* History of cancer, other than non-melanomatous skin cancer~* Retinopathy~* Papilledema Other protocol defined inclusion/exclusion criteria may apply

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BVS857 Part A Open label (Cohort 1) (Type: EXPERIMENTAL): Participants received single doses of 0.01 mg/kg BVS857 intravenously (i.v.) on day 1, 0.01 mg/kg BVS857 subcutaneously (s.c.) on day 15, 0.03 mg/kg BVS857 s.c. on day 29, 0.06 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57.
- BVS857 Part A double blind (Cohort 2) (Type: EXPERIMENTAL): Participants received single doses of 0.03 mg/kg BVS857 i.v on day 1, 0.03 mg/kg BVS857 s.c. on day 15, 0.06 mg/kg BVS857 s.c. on day 29, 0.10 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57. (BVS857 concentrations differed on days 43 and 57.)
- Placebo Part A double blind (Cohort 2) (Type: PLACEBO_COMPARATOR): Participants received single doses of matching placebo i.v. on day 1 and matching placebo s.c. on days 15, 29, 43 and 57.
- BVS857 Part B open-label (Cohort 4) (Type: EXPERIMENTAL): Participants received 0.1 mg/kg BVS857 i.v. weekly for 12 weeks.
- BVS857 Part B double blind (Cohort 5) (Type: EXPERIMENTAL): Participants received 0.06 mg/kg (maximum 6 mg) BVS857 i.v. weekly for 12 weeks.
- Placebo Part B double blind (Cohort 5) (Type: PLACEBO_COMPARATOR): Participants received matching placebo i.v. to BVS857 weekly for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).